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Abstract Parkinson’s disease (PD), a progressive
neurodegenerative disorder, is characterized by a pref-
erential loss of dopaminergic neurons in the substantia
nigra pars compacta (SNPC). Neurons in the SNPC are
known to express tyrosine hydroxylase (TH); there-
fore, in a commonly used PD model, 6-hydroxydop-
amine (6-OHDA), a selective catecholamine
neurotoxin, induces neuronal death in SNPC. We have
shown with immunohistochemical techniques that kyn-
urenine aminotransferase-I (KAT-I), the enzyme tak-
ing part in the formation of kynurenic acid (KYNA)—
the only known endogenous selective NMDA receptor
antagonist and a potent neuroprotective agent—is also
expressed in the rat SNPC. We found that KAT-I and
TH co-exist in the very same neurons of SNPC and that
6-OHDA injected into the lateral ventricle produced
loss of the majority of nigral neurons. Densitometric
analysis proved that, in consequence of 6-OHDA
treatment, not only TH but also KAT-I immunoreac-
tivity diminished considerably in the remaining SNPC
neurons. Astrocytes in the substantia nigra were found
to express KAT-I under normal conditions; the
amount of this enzyme increased after administration
of 6-OHDA, whereas microglial cells became KAT-I
immunoreactive only after 6-OHDA treatment. Since
intrinsic KYNA in SNPC neurons is perceptibly insuY-
cient to protect them from the deleterious eVect of
6-OHDA, it is hypothesized that biochemical
approaches which increase KYNA content of the cen-
tral nervous system might prevent the deleterious
eVect of 6-OHDA and, supposedly, also the neuronal
degradation characterizing PD.
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Introduction
The molecular pathways involved in Parkinson’s dis-
ease (PD) have been studied in a wide variety of exper-
imental models designed to mimic speciWc pathogenic
events of the human disease. In the most widely used
model of PD in rats, intracerebral administration of the
catecholamine-cell-speciWc neurotoxin 6-hydroxydop-
amine (6-OHDA) was used, injected into diVerent
parts of the nigrostriatal pathway, such as the striatum,
the medial forebrain bundle, and the substantia nigra
pars compacta (SNPC). Such models may help deWne
cellular factors of cell death which are critical for nigral
degeneration [2, 6, 12, 14, 15, 34].
Although the etiology of the cellular mechanisms
underlying PD is unknown, several factors, such as
environmental and genetic elements, are known to
induce relatively selective dopaminergic cell death in
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128 Acta Neuropathol (2006) 112:127–137the substantia nigra (SN) which is accompanied by
characteristic clinical features of PD. Thus, according
to Barkats et al. [1], the neurotoxin 6-OHDA may
cause dopaminergic cell death via free radical mecha-
nisms. These investigations underline the major contri-
bution of superoxide in the process of dopaminergic
cell death induced by 6-OHDA. This has been linked
with the selective accumulation of iron in the Parkinso-
nian SN and iron-catalyzed free radical formation.
Iron-induced lipid peroxidation has been proposed as a
possible cause of nigral cell death [13].
Endogenous excitotoxins that act on the receptors
of cerebral excitatory amino acids may also play impor-
tant roles in the pathogenesis of excitotoxic brain dis-
eases: activation of excitatory amino acid receptors
results in selective neuronal death characteristic of
these disorders, including PD [4].
Kynurenic acid (KYNA) is a selective antagonist at
the strychnine-insensitive glycine site of the NMDA
receptor [20, 35]; therefore, it is considered to be a potent
neuroprotective agent [28]. KYNA is produced from its
biological precursor, L-kynurenine, by the enzyme kynu-
renine aminotransferase (KAT), and plays an important
role in the tryptophan metabolism of the central nervous
system (CNS) [38]. According to the biochemical analysis
of tissue homogenates, KAT activity is present in rat and
human brains [11, 29, 30]. Two distinctly diVerent iso-
forms of KAT appear to be responsible for the synthesis
of KYNA under physiological conditions. One of these,
KAT-I, is a soluble enzyme; KAT-I antibodies were
raised by Okuno and co-workers [29] and were used in
the immunohistochemical investigations [7, 18, 32].
Another enzyme, KAT-II, was identiWed by Northern
blot mRNA analysis in the human brain [30]. Immuno-
histochemical studies using anti-KAT-I antibody local-
ized KAT-I immunoreactive (IR) mainly in the
astrocytes of forebrain structures [7, 22]. L-Kynurenine is
known to cross the blood–brain barrier; it can be transa-
minated to KYNA, the excitatory amino acid receptor
antagonist, by the enzyme activity of KAT, known to be
primarily located in glia [30]. Furthermore, it has been
shown that glial cells possess the uptake mechanisms for
L-kynurenine, and can release KYNA [36, 37]. At the
same time, KAT-I IR was observed also in several nerve
cells [30, 32], mainly in the medulla oblongata and spinal
cord [18].
In the course of our earlier investigations, we studied
the eVects of sodium azide [22], 3-nitropropionic acid
[5], and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
(MPTP) treatment on KAT-I of various nerve and glial
Fig. 1 Normal distribution of KAT-I and TH in the SN. a KAT-I
IR outlines the SNPC (scale bar, 100 m). b Under high power,
the granular localization of the KAT-I IR is conspicuous (arrow).
KAT-I granules in the perikaryon surround the nucleus; granules
are also present in the proximal parts of the cell processes (inset:
scale bar, 10 m). The glial cells additionally exert KAT-I IR
(arrowhead) (scale bar, 40 m). Inset: KAT-I IR neuron at high
power (scale bar, 10 m). c The TH IR outlines the SNPC. The
SNPR is almost totally occupied by TH IR processes of dopami-
nergic neurons (asterisks) (scale bar, 100 m). d The localization
of TH in the neuronal cytoplasm is homogeneous (arrow), as seen
at high power (scale bar, 40 m). The TH staining of the dopami-
nergic neurons is especially striking in the inset (scale bar, 10 m)123
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SN, where KAT-I and tyrosine hydroxylase (TH) co-
exist in neuronal cytoplasms [21], MPTP treatment of
mice resulted in decrease of number and optical density
of KAT-I IR neurons, whereas KAT-I IR of glial cells
was increased. Since most of the relevant studies, using
6-OHDA as a speciWc neurotoxin of dopaminergic neu-
rons, were performed on the SN of rats, we decided to
investigate, with immunocytochemical methods,
whether KAT-I is also present in the nerve and glial
cells of the SNPC of the rat, similarly to those of the
mouse. Another question related to the possible eVect of
the 6-OHDA-induced nerve cell degeneration upon
KAT-I. Finally, we investigated the distribution of
KAT-I in the glial cells of the SN under normal condi-
tions and after 6-OHDA administration.
Experimental procedures
Animals
Investigations were performed on 35 adult male
albino rats (Rattus norvegicus albus), Wistar strain,
250-g body weight. Care of the animals complied with
the guidelines of the Hungarian Ministry of Welfare;
experiments were carried out in accordance with the
European Communities Council Directive (24
November 1986; 86/609/EEC). The animals were
divided into six groups: one group was the absolute
control and the second group was injected into the
left lateral ventricle with physiologic saline; four
groups of rats were stereotactically injected into the
left lateral ventricle with graded doses of 6-OHDA,
ranging from 40 to 800 g/kg. For stereotactic sur-
gery, 6-OHDA (Sigma-Aldrich, Steinheim, Ger-
many) was dissolved in PBS. Stereotactic injections
were performed under pentobarbital anesthesia.
Coordinates of the injections were as follows: AP:
-0.8 mm from the bregma, ML: ¡1.4 mm from the
sutura sagittalis, and V (depth): 4.0 mm from the skull
[31]. Rats were unilaterally injected into the left lat-
eral ventricle using a Hamilton microsyringe. The
needle was left in place for an additional 2 min and
then slowly withdrawn. The correct positioning of the
cannula was checked by dissection of the brain at the
end of the experiment. After a survival time of 23
days, rats were deeply anesthetized with chloral
hydrate (4 g/kg i.p.) and transcardially perfused with
a Xush of 40 ml of 0.1 M PBS (pH 7.4), which was fol-
lowed by 500 ml of PLP Wxative, consisting of para-
formaldehyde, lysine, and periodate, buVered to pH
7.4 with 0.4 M PBS [25]. Brains were removed in toto,
both sides of the SN were excised and postWxed in the
same Wxative for 3 h at 4°C. The samples were pro-
cessed in a graded series of sucrose (10, 20, and 30%)
dissolved in PBS, surrounded by Tissue-Tek embed-
ding medium (Miles, Diagnostics Division, Elkhart,
IN, USA) and frozen in the chamber of the cryostat at
¡22°C. Transverse consecutive sections, 30 m thick,
were obtained from the entire SN.
Fig. 2 Electron microscopy of KAT-I IR in the nerve cells in the
SNPC. a In the perikaryon of a normal nerve cell, the KAT-I IR
appears in granular form (arrows), surrounding the nucleus
(er: endoplasmic reticulum). a* The granules indicated by arrows
in a, at higher magniWcation. Some of the “granules” correspond
to multivesicular bodies. b TH IR in the perikaryon of a normal
neuron. The end product of the IR is attached to the surfaces of
ribosomes (arrows). MagniWcation identical to that in a123
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Endogenous peroxidase was blocked with 2% H2O2
dissolved in methanol. Sections were processed accord-
ing to the avidin–biotin system (Vectastain ABC Elite,
Vector Laboratories, Burlingame, CA, USA); immu-
noreactivity was visualized with diaminobenzidine
(DAB, Polysciences, Inc., Warrington, PA, USA), to
which hydrogen peroxide had been added (3 l of
H2O2 to 10 ml of 0.05% DAB). Sections were mounted
on gelatin-pretreated glass slides, dehydrated in a
graded series of ethanol, and processed through car-
bol-xylene. Slides were coverslipped with Permount
(Fisher, Fair Lawn, NJ, USA).
Demonstration of KAT-I
The sections were incubated overnight at room tem-
perature in anti-KAT-I polyclonal antibody raised in
rabbit against rat kidney KAT-I [29], (1:1,500), in
0.01 M pH 7.4 PBS, containing Triton X-100 and nor-
mal goat serum. This was followed by 90-min incuba-
tion in biotinylated anti-rabbit secondary antibody.
Also, TH was demonstrated by incubation at room
temperature overnight in anti-TH monoclonal anti-
body (Sigma) diluted to 1:10,000 in 0.01 M PBS (pH
7.4) containing 0.3% Triton X-100 and normal goat
serum. Sections were incubated for 90 min in biotinyla-
ted anti-mouse secondary antibody. For the demon-
stration of glial Wbrillary acidic protein (GFAP),
sections were incubated in anti-GFAP raised in mouse
(Sigma), diluted to 1:400, at room temperature over-
night, followed by a 90-min incubation in biotinylated
anti-mouse secondary antibody.
Microglial cells were demonstrated with CD11b
(Chemicon International, Inc., Temecula, CA, USA)
anti-rat primary antibody raised in mouse in a dilution
of 1:400 at room temperature overnight, followed by a
90-min incubation in biotinylated anti-mouse second-
ary antibody.
Fig. 3 Double staining of KAT-I and TH at the level of immune
Xuorescence. a KAT-I IR is located in the neurons of the SNPC
(arrows) and in the glial cells (arrowheads) (scale bar, 30 m). b
TH IR is located exclusively in neurons (arrows); abundant neu-
ronal processes are also TH IR (scale bar, 30 m). c Superposition
of the KAT-I and TH in the identical areas of the section. It is
apparent that the neurons contain both KAT-I and TH (scale bar,
30 m). d The area outlined in c with immersion optics. Yellow
rings around the nuclei denote KAT-I IR. The glial cells exert
only green Xuorescence, indicating KAT-I IR (arrowhead) (scale
bar, 15 m)123
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was assessed by the following treatments:
1. Omission of the Wrst (speciWc) antiserum.
2. Use of normal rabbit (or mouse, resp.) serum
instead of the speciWc antiserum.
3. Treatment according to the avidin–biotin complex
method, from which one of the steps had been
omitted.
4. Preabsorbtion of the speciWc antibody with pure
rat kidney KAT at 4°C for 24 h.
None of these specimens has shown any reaction.
For double staining of KAT-I and TH (immunoXuo-
rescence technique), 30-m cryostat sections of the SN
were collected on precoated slides. Using the simulta-
neous method, KAT-I antiserum, raised in rabbit [29]
(1:1,500), and TH antiserum, raised in sheep (Chem-
icon) 1:10,000, were used as primary antibodies at
room temperature overnight. The secondary serum
was a mixture of FITC-conjugated donkey anti-rabbit
IgG and Rhodamin Red-conjugated donkey anti-sheep
IgG (Jackson Immuno Research Laboratories, Bar
Harbor, ME, USA) in a dilution of 1:200, for 2 h at
room temperature. After three rinses in PBS, the sec-
tions were coverslipped with polyvinyl alcohol mount-
ing medium (DABCO Antifading, Fluka Chemie
GmbH, Buch, Germany).
The veriWcation of immunoreaction speciWcity in the
SNPC proved that after omission of TH antibody from
the primary serum, the subsequent visualization with
the secondary antisera did not result in the Xuores-
cence normally characterizing the TH cells.
Also, double staining of KAT-I and CD11b (immu-
noXuorescence technique) was performed on cryostat
sections, collected on precoated slides. The simulta-
neous method was used: KAT-I antiserum, raised in
rabbit (1:1,500), and CD11b antiserum (Chemicon),
raised in mouse (1:400), were used as primary antibod-
ies, at room temperature overnight. After rinsing in
PBS, the sections were treated with biotinylated anti-
mouse IgG (Vector) 1:200 for 90 min. Incubation was
followed in a medium containing FITC-conjugated
anti-rabbit IgG (Vector) and streptavidin-conjugated
CY 3 (Jackson) in a dilution of 1:200, for 2 h.
Finally for the double staining of KAT-I and GFAP
(immunoXuorescence), KAT-I antiserum, raised in rab-
bit (1:1,500) and GFAP antiserum (Santa Cruz Biotech-
nology, Inc., Santa Cruz, CA, USA) raised in goat
(1:500), were used as primary antibodies. The incubation
was performed at room temperature overnight, followed
by treatment in a secondary antibody containing FITC-
conjugated donkey anti-rabbit IgG and Rhodamin Red-
conjugated donkey anti-sheep IgG (1:200) for 2 h.
Analysis of the Xuorescent images and photography
of the sections were performed using a Nikon Eclipse
E600 microscope equipped with B-2A (EX: 450–490)
and G-2A (EX: 510–560) Wlters and a Spot RT Slider
digital camera (1,600 £ 1,200 pixels in 24 bits). The
software used was the Image Pro Plus 4.5 morphome-
try (Media Cybernetics, Silver Spring, MD, USA). The
emitted Xuorescence was determined by intensity mea-
surement. We have been working with true color
Fig. 4 EVects of 400 and 800 g/kg of 6-OHDA, 23 days after
injection of the drug into the lateral ventricle. a Disappearance of
KAT-I IR, mainly from the middle area of the SNPC, 23 days af-
ter treatment with 400 g/kg of 6-OHDA (arrows) (scale bar,
100 m). b Disappearance of KAT-I IR from the middle and
lateral areas of the SNPC, 23 days after treatment with 800 g/kg
6-OHDA (arrow) (scale bar, 100 m). c Disorganization of KAT-I
IR neurons, 23 days after treatment with 400 g/kg of 6-OHDA,
at high power (arrows) (scale bar, 10 m). d The shrinkage of
the KAT-I IR neurons is striking 23 days after treatment with
800 g/kg of 6-OHDA, at high power (arrows) (scale bar, 10 m)123
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measured the luminosity of the green (for KAT-I IR
cells) or the red (for TH, GFAP, and CD11b IR cells)
channel. The analysis was performed in 6-6 randomly
selected sections, in Wve areas of interest (AOI) in each
group, using a 40£ front lens (NA: 0.7). AOI was a
rectangular box measuring 30 £ 45 m2. In each mea-
surement, we used a linear intensity scale; Wnally, the
intensity of the black level was subtracted from the val-
ues obtained.
Electron microscopy
After transcardial PLP Wxation, KAT-I and TH were
visualized in vibratome sections (50 m), using the
same immunocytochemical procedures as employed
for light microscopy, except that Triton X-100 was
omitted from the incubation medium. After the DAB
reaction, the sections were additionally Wxed in
buVered 1% osmic acid solution for 1 h. Following
dehydration, the sections were Xat-embedded on liquid
Fig. 5 Densitometric analysis of KAT-I IR and TH IR in the
SNPC under normal conditions (C) and 23 days after 6-OHDA
treatment
Fig. 6 Double staining of 
KAT-I and glial cell markers. 
a Astroglial cells (arrows) and 
neurons (arrowheads) exhibit 
KAT-I IR in the SN under 
normal conditions (scale bar, 
200 m). b Astroglial cells 
stained with the speciWc mark-
er GFAP in the SN under nor-
mal conditions (arrows) (scale 
bar, 200 m). c The superposi-
tion proves that the KAT-I IR 
and GFAP IR areas are iden-
tical (arrows). The neurons 
exert only KAT-I IR (arrow-
heads) (scale bar, 200 m). 
d–f Double staining by KAT-I 
and the microglia-speciWc 
marker CD11b under normal 
conditions. d Only the neu-
rons (arrowhead) and astrog-
lial cells (arrow) exhibit KAT-
I IR (scale bar, 30 m). e Mi-
croglial cells stained by the 
speciWc marker CD11b (arrow 
with asterisk) (scale bar, 
30 m). f Superposition of 
KAT-I and CD11b IR in the 
same area. Microglial cells ap-
pear red (arrow with asterisk), 
whereas neurons (arrowhead) 
and astroglial cells (arrow) are 
green (scale bar, 30 m)123
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areas were excised with a razor blade under light
microscopic control, remounted to prepolymerized
blocks, and sectioned on a Reichert Ultrotome
equipped with a diamond knife. Serial sections of silver
interference color were collected on copper slot grids
and stained with uranyl acetate and lead citrate. The
sections were analyzed with a Zeiss Opton 902 electron
microscope.
Results
Neurons
Under normal conditions, KAT-I IR outlined SNPC
(Fig. 1a). High-power investigation revealed that KAT-I
IR was located in a granular form in the perinuclear
cytoplasm and in the proximal parts of nerve cell pro-
cesses (Fig. 1b and inset), as well as in glial cell bodies.
TH IR exhibited a similar localization in neuronal cyto-
plasms, both in SNPC and in SNPR; TH IR was also
present in numerous neuronal processes throughout
almost the entire SN (Fig. 1c). At high magniWcation, it
was evident that TH IR of neurons was diVuse (Fig. 1d
and inset), in contrast to the granular localization of
KAT-I. In accordance with the light microscopic studies,
electron microscopy revealed that KAT-I IR was local-
ized in granules scattered in the cytoplasm, preferen-
tially around the nucleus. On the basis of their
ultrastructural appearance, these granules corresponded
to multivesicular bodies (Fig. 2a, a*). In contrast, TH IR
was localized in the endoplasmic reticulum where the
product of the IR was attached to the surfaces of ribo-
somes (Fig. 2b).
Co-localization of KAT-I and TH was proved by
double staining at the level of Xuorescence microscopy.
KAT-I IR was, however, less intensely Xuorescent than
TH IR. Processes of TH IR neurons were TH-immu-
nopositive (Fig. 3a–d); glial cells also exerted KAT-I
(Fig. 3a, c, d). Twenty-three days after injection of
400 g/kg 6-OHDA in the lateral ventricle, KAT-I IR
disappeared mainly from the middle area of SNPC
(Fig. 4a), while after injection of 800 g/kg, KAT-I dis-
appeared from both the middle and lateral areas of
SNPC (Fig. 4b). Shrinkage and degradation of KAT-I
IR neurons in SNPC was especially striking at higher
magniWcation (Fig. 4c, d) Injection of 6-OHDA into
Fig. 7 Astroglial and microglial changes induced by 6-OHDA. a
Microglial cells (arrows) stained with the speciWc marker CD11b,
using the ABC immunohistochemical technique. Normal control
(scale bar, 40 m). Inset: characteristic ramiWcations of one of the
microglial cells (scale bar, 10 m). b Twenty-three days after the
injection of 800 g/kg of 6-OHDA, the number of microglial cells
is markedly increased, especially in the SNPC (arrows). Staining
with CD11b (scale bar, 40 m). Inset: one of the swollen microg-
lial cells, displaying thickened processes (scale bar, 10 m).
c Astrocytes (arrows) stained with the speciWc marker GFAP, us-
ing the ABC technique. Normal control (scale bar, 40 m). In the
inset, one of the astroglial cells is shown at higher power (scale
bar, 10 m). d Twenty-three days after the injection of 800 g/kg
of 6-OHDA: the number of astrocytes is markedly increased,
especially in the SNPC. GFAP staining (scale bar, 40 m). In the
inset, one of the astroglial cells, with increased ramiWcation of the
processes, is shown at higher power (scale bar, 10 m)123
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the number, density (Fig. 5) and distribution of dopa-
minergic neurons in SNPC. Counterstaining with cresyl
violet revealed that in animals treated with 40 g/kg
6-OHDA, 67 § 5% of TH IR SNPC neurons survived
neurotoxin treatment after 23 days without any visible
sign of deterioration; the relevant percentage in ani-
mals treated with 200 g/kg 6-OHDA was 33 § 6%, in
animals treated with 400 g/kg 6-OHDA was 24 § 6%,
while in those treated with 800 g/kg 6-OHDA was
10 § 3%.
Glia
Under normal conditions, astroglial cells in the SN
showed KAT-I IR (Fig. 6a) which co-localized with
GFAP (Fig. 6b, c). Neurons in the same specimens
were visible in green color (Fig. 6a, c) indicating the
presence of KAT-I. Microglial cells, however, identi-
Wed with the speciWc microglia marker CD11b
(Fig. 6e), did not show any KAT-I IR under normal
conditions (Fig. 6d). After superposition of KAT-I and
CD11b IR (Fig. 6f), neurons expressing KAT-I
appeared in green color, while CD11b-stained microg-
lia appeared in red color.
Immunohistochemical studies performed with the
speciWc microglial marker CD11b (Fig. 7a) revealed
that the number of microglial cells increased markedly
23 days after 800 g/kg 6-OHDA treatment (Fig. 7b).
At the same time, also the microglial processes have
shown severe alterations (Fig. 7a, b, insets) insofar as
microglial processes became more voluminous and
elaborate.
Similar alterations were found in astrocytes stained
with the speciWc astroglial marker GFAP: as compared
with the controls (Fig. 7c and inset), the number of
astroglial somata and processes increased considerably
23 days after 6-OHDA treatment (Fig. 7d and inset).
Densitometric analysis indicated that KAT-I IR
increased signiWcantly in glial cells of SNPC after
6-OHDA treatment, though the increase was far less
striking than that of CD11b and GFAP, the speciWc
markers of microglia and astroglia, respectively
(Fig. 8a, b). This increase was probably due to cluster-
ing of glial cells—especially microglia—around
aVected neurons.
Electron microscopy revealed that, while some of
the KAT-I IR granules characterizing SNPC neurons
still existed 9 days after 40 g/kg 6-OHDA treatment,
large dense bodies indicating incipient degeneration
appeared in the cytoplasms of nerve cells (Fig. 9a).
Twenty-three days after 800 g/kg 6-OHDA treat-
ment, degenerating KAT-I IR nerve cells were charac-
terized by shrinkage and darkening of the whole cell
body; the perikaryon was surrounded by glial processes
(Fig. 9b).
Discussion
Animal models are still of use in facilitating an under-
standing of the neurodegeneration characteristics of
PD. In the present paper, we have shown that unilateral
injections of 6-OHDA into the lateral ventricle of the
adult rat lead to a dose-dependent, gradual loss of TH
and KAT-I from the SNPC. Intracerebroventricular
administration [33] results in poor diVusion; nevertheless,
Fig. 8 Densitometric analysis of KAT-I IR and speciWc markers
in glial cells in the SN. a SigniWcant increase in KAT-I IR in the
microglial cells 23 days after treatment with 800 g/kg of 6-OH-
DA, although the increase is far less than that in the speciWc
microglia marker CD11b. b SigniWcant increase in KAT-I IR in
the astroglial cells 23 days after treatment with 800 g/kg of
6-OHDA, although the increase is less than that in the speciWc as-
troglial marker GFAP123
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cells located in the SN (commonly observed after injec-
tion into the striatum) can be avoided. At the highest
dose of 6-OHDA that we employed (800 g/kg), the
TH and KAT-I IR of the nerve cells diminished consid-
erably in the SNPC, either transiently or irreversibly, in
consequence of cell death [23] or apoptosis [2, 24].
The presence of KAT-I (CCBL1 according to the
HUGO nomenclature [8]) in the glial cells is a well-
known fact [7, 22, 30]. To date, however, only certain
neurons in the CNS have been shown to contain KAT-I
[7, 18, 21, 22, 30, 32]. We report here on the presence of
KAT-I in the SN neurons in the rat and its co-existence
with TH, similarly as described earlier in the mouse [21].
After 6-OHDA treatment, the optical intensity of
the speciWc markers GFAP and CD11b increased in
the SNPC, due to the accumulation of astroglial and
microglial cells. This observation is in accord with the
results of Iravani et al. [16], who found that the loss of
dopaminergic neurons from the SN in PD may result
from the inXammation-induced proliferation of
microglia and reactive macrophages, accompanied by
intense GFAP IR astrocytosis in the SN. Similar
increases in GFAP IR astrocytes and CD11b IR
microglial cells were earlier observed [21] in the SN
of mice after MPTP treatment. Under normal condi-
tions, only the astrocytes contain KAT-I; however,
after 6-OHDA treatment, the microglial cells also were
found to be KAT-I IR, even though the amount of
KAT-I was still larger in the astrocytes than in the
microglial cells, probably because the astrocytes con-
tained KAT-I even under normal conditions.
Although the origin of the KAT-I in the microglial
cells after 6-OHDA treatment is unknown, it can be
assumed that it is derived from internalized KAT-I
immunopositive neurons. Guillemin et al. [10] con-
cluded that astrocytes, which alone are neuroprotec-
tive, become indirectly neurotoxic in the presence of
microglia, since microglial cells produce large amounts
of kynurenine that can be metabolized to quinolinic
acid. Quinolinic acid has recently been shown to
induce chemokine production and chemokine receptor
expression in the astrocytes [9].
Reactive astrocytes, or rather functionally activated
astrocytes, have been observed in numerous 6-OHDA
animal models of PD. Although the astrocytes have
traditionally been assumed to impede neuronal regen-
eration, activated microglia and reactive astrocytes
have been found in the area of neuronal loss [39]; these
glial elements possibly contribute to the inXammatory
process by releasing prostaglandins or cytokines, and
may mediate neuroprotection by releasing trophic fac-
tors [3]. Recent studies indicate that reactive astrocytes
may oVer crucial beneWt in the functional recovery
from brain injuries: for instance, Vila et al. [40] suggest
that the glial response may be the source of trophic fac-
tors protecting against glutamate and reactive oxygen
compounds. Accordingly, Chen et al. [3] hypothesize
that reactive astrocytes may play important roles in the
protection of dopaminergic neurons in the SN. Ishida
Fig. 9 Electron microscopy 
of KAT-I IR in degenerating 
nerve cells of the SNPC. a 
Portion of the cytoplasm of a 
KAT-I IR neuron 12 days af-
ter the injection of 40 g/kg of 
6-OHDA. In spite of the pres-
ence of a few KAT-I IR gran-
ules (arrow), large 
degenerative dense bodies ap-
pear (asterisk). er: endoplas-
mic reticulum. b Remnants of 
a shrunken and darkened 
nerve cells in the SNPC 23 
days after treatment with 
800 g/kg of 6-OHDA. Resid-
ual KAT-I IR is marked with 
asterisks. Glial cell processes 
(gl) surround the debris of the 
cytoplasm (cy). The magniW-
cation is identical to that in a123
136 Acta Neuropathol (2006) 112:127–137et al. [17] suggest that the increased expression of pro-
tease-activated receptor-1 by the astrocytes in the
SNPC provides neuroprotection during the progres-
sion of PD pathology. This is in line with our observa-
tion that the KAT-I IR of the astrocytes was increased
after 6-OHDA treatment.
What is the role of KAT-I in the nigral neurons?
Following the loss of dopamine, enhanced NMDA
receptor-mediated synaptic transmission was detected
in the striatum [26]; the situation may possibly be simi-
lar in the SN. On the other hand, excess glutamatergic
transmission at NMDA receptors has recently been
hypothesized to play a role in the expression of the
symptomatology of PD [19]. In view of the neuropro-
tective role of KYNA synthesized by KAT-I, it may be
assumed that KAT-I participates in an intrinsic, genu-
ine defense mechanism, protecting the nigral dopami-
nergic neurons from the consequences of minor
injuries occurring throughout life.
The content of KYNA in the SNPC neurons is
apparently insuYcient to protect them from the delete-
rious eVect of 6-OHDA; however, ongoing neurobio-
logical studies [27] may reveal new approaches to
increase the amount of KYNA in the SNPC, and this,
together with the glial contribution outlined above,
might possibly provide neuroprotection and prevent
the neuropathological consequences of PD.
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